FAYUVI

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
FAYUVI
Generic name
REBISUFLIGENE ETISPARVOVEC-HOPF
Manufacturer
Ultragenyx Pharmaceutical Inc.
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
996fc33a-26d3-4fae-bd0c-a2edd7764539
SPL ID
453f2a2e-d064-41ba-a715-11285409d478
Version
1
Effective date
2026-10-01
Source export date
2026-11-13
Source partition
6
Source file
https://download.open.fda.gov/drug/label/drug-label-0006-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/a79c47b73cf1c0b9829667844daa083c5114cf268a1839f963bc5617e9060c4f/drug-label-0006-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:20:49

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Hepatotoxicity: Monitor liver enzymes and total bilirubin levels until 2 weeks after the corticosteroid taper is complete and as clinically indicated. Continue to monitor patients who develop liver enzyme elevations until liver enzymes return to baseline. ( 2.3 , 5.1 ) Thrombocytopenia: Monitor platelet counts weekly for the first 4 weeks, then monthly for 6 months following infusion ( 2.3 , 5.2 ) Thrombotic Microangiopathy (TMA): If signs and symptoms occur, promptly undertake further diagnostic evaluation for hemolytic anemia and renal dysfunction. ( 5.3 ) Hypersensitivity and Infusion Reactions: Monitor during and after infusion. If symptoms occur, pause the infusion. If appropriate, restart at a slower rate after the infusion reaction has resolved. ( 5.4 ) Risk of Malignancy: In the event that a malignancy occurs, contact Ultragenyx Pharmaceutical Inc. at 1-888-756-8657. ( 5.5 ) 5.1 Hepatotoxicity Elevated liver enzymes (ALT, AST, and GGT) were observed in clinical studies of FAYUVI [see Adverse Reactions (6.1) ] . Prior to FAYUVI infusion, assess liver function by clinical examination and laboratory testing (ALT, AST, GGT and total bilirubin) and evaluate liver-related medical history. Administer corticosteroids to all patients before and after FAYUVI infusion. If abnormalities are observed, adjust the corticosteroid treatment regimen, including increasing the dose and/or prolonging the corticosteroid taper period [see Dosage and Administration (2.1) ] . Closely monitor ALT, AST, GGT and total bilirubin levels after FAYUVI administration until 2 weeks after the corticosteroid taper is complete and as clinically indicated. Continue to monitor liver function in all patients who develop elevated liver enzymes until levels return to baseline [see Dosage and Administration (2.3) ] . 5.2 Thrombocytopenia Decreased platelet counts were observed in clinical studies of FAYUVI [ see Adverse Reactions (6.1) ]. Prior to FAYUVI infusion, assess platelet counts. Monitor platelet counts weekly for the first 4 weeks, then monthly for 6 months following infusion. Continue monitoring as clinically indicated [see Dosage and Administration (2.3) ] . 5.3 Thrombotic Microangiopathy Thrombotic microangiopathy (TMA) has been reported in association with AAV gene therapies. While there have been no cases of TMA associated with FAYUVI in clinical studies, laboratory and clinical monitoring for TMA following FAYUVI infusion is recommended. Monitor platelet counts closely within the first 4 weeks following FAYUVI infusion [see Warnings and Precautions (5.2) ] . Signs and symptoms of TMA may include, but are not limited to, thrombocytopenia, hemolytic anemia, easy bruising, hypertension, seizures, decreased urine output and renal dysfunction. If TMA is suspected, immediately consult a pediatric hematologist and/or nephrologist for further evaluation and management as clinically indicated. 5.4 Hypersensitivity and Infusion Reactions Infusion reactions, including hypersensitivity reactions and anaphylaxis, may occur with infusion of FAYUVI. Symptoms may include but are not limited to hypotension, pyrexia, palpitation, nausea, vomiting, chills, or headache. Closely monitor patients for clinical signs and symptoms of infusion reactions, including hypersensitivity reactions, and monitor vital signs during and after completion of FAYUVI infusion as clinically indicated. In the event of an infusion reaction during administration, pause the infusion and provide supportive care according to clinical practice. If the infusion is paused and continued administration is appropriate, restart at a slower rate after the infusion reaction has resolved [see Dosage and Administration (2.3) ] . 5.5 Risk of Malignancy Malignancy may occur following treatment with FAYUVI due to potential integration of AAV vector DNA into the genome. In the event of a malignancy, contact Ultragenyx Pharmaceutical Inc. at 1-888-756-8657.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6 ADVERSE REACTIONS Most common adverse reactions (≥5%): liver enzyme increased, vomiting, pyrexia, white cell count decreased, decreased appetite, platelet count decreased, nausea, amylase increased. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Ultragenyx Pharmaceutical Inc. at 1-888-756-8657 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of FAYUVI was evaluated in 33 pediatric patients with MPS IIIA who received a single intravenous infusion of FAYUVI in 3 clinical studies: 2 open-label, single-arm studies (Study 1 and Study 3) and 1 long-term follow-up study (Study 2) which enrolled patients who participated in one of the prior studies [see Clinical Studies (14) ] . Twenty-seven patients received the recommended dose of 3.0 × 10 13 vg/kg. The mean age at the time of treatment was 38.5 months (range: 3.0 months to 9.2 years) and the mean weight was 17.1 kg (range: 3.9 to 31.2 kg). Patients treated with the recommended dose were 96% White and 4% of multiple race; 11% were Hispanic or Latino. The median duration of follow-up following FAYUVI infusion was 4.1 years (range: 7.0 months to 7.8 years). Adverse reactions in patients who received the recommended dose of 3.0 × 10 13 vg/kg of FAYUVI (N=27) in clinical studies are listed in Table 3. Table 3: Adverse Reactions Occurring in ≥ 5% of Patients Following Treatment with FAYUVI Adverse Reactions Number of Patients (%) N=27 Liver enzyme increased Includes aspartate aminotransferase (AST) increased, alanine aminotransferase (ALT) increased, and gamma-glutamyl transferase (GGT) increased. 23 (85%) Vomiting All adverse reactions were of Grade 1 or Grade 2 severity. 18 (67%) Abnormal behavior , Includes abnormal behavior, affect lability, aggression, agitation, irritability, nervousness, anxiety, attention deficit hyperactivity disorder, behavior disorder, insomnia, mental status changes, and related behavioral terms. 15 (56%) Diarrhea 13 (48%) Pyrexia 11 (41%) White cell count decreased Includes white blood cell count decreased, leukopenia, lymphocyte count decreased, lymphopenia, and neutropenia. 8 (30%) Cushingoid features 8 (30%) Decreased appetite 6 (22%) Platelet count decreased , Includes platelet count decreased and thrombocytopenia. 5 (19%) Anemia 5 (19%) Constipation 4 (15%) Nausea 3 (11%) Amylase increased 3 (11%) Alkaline phosphatase increased 3 (11%) Seizure Includes seizure, epilepsy, status epilepticus, partial seizures 3 (11%) Hepatomegaly 3 (11%) Muscle spasticity 2 (7%) Hypokalemia 2 (7%) Gait disturbance 2 (7%) Adrenal insufficiency 2 (7%) Hepatotoxicity In clinical trials, 85% (23/27) of patients receiving the recommended dose of FAYUVI experienced adverse reactions associated with liver enzyme elevations (AST, ALT, and/or GGT). Most liver enzyme elevations were less than Grade 3 in severity, and none were associated with elevations of total bilirubin. A single Grade 3 ALT elevation in one patient occurred in the setting of gastroenteritis 62 days following FAYUVI infusion and resolved spontaneously within 8 days. The time to first onset was most frequently within the first 14 days and ranged from 2 days to 30.3 months following FAYUVI infusion. All liver enzyme elevations resolved within 6 days to 40.6 months of onset, except in 2 patients where slight elevations persisted. Neutropenia In clinical trials, 22% (6/27) of patients receiving the recommended dose of FAYUVI experienced neutropenia. One patient experienced Grade 3 neutropenia, and the remaining events were of Grade 1 or 2 severity.

adverse reactions table

<table width="80%"> <caption>Table 3: Adverse Reactions Occurring in &#x2265; 5% of Patients Following Treatment with FAYUVI </caption> <col width="55%" align="left" valign="top"/> <col width="45%" align="center" valign="top"/> <thead> <tr> <th styleCode="Lrule Rrule" valign="middle">Adverse Reactions</th> <th styleCode="Rrule">Number of Patients (%) N=27</th> </tr> </thead> <tbody> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Liver enzyme increased<footnote>Includes aspartate aminotransferase (AST) increased, alanine aminotransferase (ALT) increased, and gamma-glutamyl transferase (GGT) increased.</footnote> </td> <td styleCode="Rrule">23 (85%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Vomiting<footnote ID="t3ftb">All adverse reactions were of Grade 1 or Grade 2 severity.</footnote> </td> <td styleCode="Rrule">18 (67%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Abnormal behavior<footnoteRef IDREF="t3ftb"/> <sup>,</sup> <footnote>Includes abnormal behavior, affect lability, aggression, agitation, irritability, nervousness, anxiety, attention deficit hyperactivity disorder, behavior disorder, insomnia, mental status changes, and related behavioral terms.</footnote> </td> <td styleCode="Rrule">15 (56%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Diarrhea<footnoteRef IDREF="t3ftb"/> </td> <td styleCode="Rrule">13 (48%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Pyrexia<footnoteRef IDREF="t3ftb"/> </td> <td styleCode="Rrule">11 (41%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">White cell count decreased<footnote>Includes white blood cell count decreased, leukopenia, lymphocyte count decreased, lymphopenia, and neutropenia.</footnote> </td> <td styleCode="Rrule">8 (30%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Cushingoid features<footnoteRef IDREF="t3ftb"/> </td> <td styleCode="Rrule">8 (30%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Decreased appetite<footnoteRef IDREF="t3ftb"/> </td> <td styleCode="Rrule">6 (22%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Platelet count decreased<footnoteRef IDREF="t3ftb"/> <sup>,</sup> <footnote>Includes platelet count decreased and thrombocytopenia. </footnote> </td> <td styleCode="Rrule">5 (19%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Anemia<footnoteRef IDREF="t3ftb"/> </td> <td styleCode="Rrule">5 (19%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Constipation<footnoteRef IDREF="t3ftb"/> </td> <td styleCode="Rrule">4 (15%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Nausea<footnoteRef IDREF="t3ftb"/> </td> <td styleCode="Rrule">3 (11%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Amylase increased<footnoteRef IDREF="t3ftb"/> </td> <td styleCode="Rrule">3 (11%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Alkaline phosphatase increased<footnoteRef IDREF="t3ftb"/> </td> <td styleCode="Rrule">3 (11%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Seizure<footnote>Includes seizure, epilepsy, status epilepticus, partial seizures</footnote> </td> <td styleCode="Rrule">3 (11%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Hepatomegaly<footnoteRef IDREF="t3ftb"/> </td> <td styleCode="Rrule">3 (11%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Muscle spasticity<footnoteRef IDREF="t3ftb"/> </td> <td styleCode="Rrule">2 (7%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Hypokalemia<footnoteRef IDREF="t3ftb"/> </td> <td styleCode="Rrule">2 (7%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Gait disturbance</td> <td styleCode="Rrule">2 (7%)</td> </tr> <tr> <td styleCode="Lrule Rrule">Adrenal insufficiency<footnoteRef IDREF="t3ftb"/> </td> <td styleCode="Rrule">2 (7%)</td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.